Healthcare-associated Infectious Disease Diagnostics Market - Global Forecast 2025-2032

Healthcare-associated infectious disease diagnostics are evolving rapidly, presenting new challenges and significant opportunities for healthcare providers, diagnostic companies, and policymakers. This environment underscores the need for robust, actionable insights to support strategic decisions and maintain competitive advantage.

Market Snapshot: Healthcare-Associated Infectious Disease Diagnostics Market

The Healthcare-associated Infectious Disease Diagnostics Market grew from USD 4.37 billion in 2024 to USD 4.76 billion in 2025. It is expected to continue growing at a CAGR of 8.60%, reaching USD 8.47 billion by 2032. This sustained expansion reflects rising global concern over hospital-acquired infections and the growing integration of advanced technologies by both public and private medical facilities. Market momentum is influenced by increasing demand for accurate and timely diagnostic solutions, driving shifts in testing practices and investment strategies worldwide.

Scope & Segmentation

• Test Method: Immunoassays such as chemiluminescent immunoassay, ELISA, and lateral flow assays; microbiology tests including aerobic and anaerobic culture, microscopy, and sensitivity testing; and molecular diagnostics, notably isothermal amplification, PCR, and sequencing.
• Pathogen Type: Diagnostic solutions target a spectrum of microorganisms, including bacterial species like Clostridium difficile, Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus; fungal genera such as Aspergillus, Candida, and Cryptococcus neoformans; parasitic infections (malaria parasites, Toxoplasma gondii); and viral agents such as coronavirus, influenza virus, norovirus, and respiratory syncytial virus.
• End User: The primary end users include independent and reference diagnostic laboratories, hospitals leveraging clinical pathology and microbiology labs, clinics, emergency departments, and long-term care facilities reliant on point-of-care solutions.
• Sample Type: Key specimen types comprise blood (serum, whole blood), cerebrospinal fluid, respiratory specimens (bronchoalveolar lavage, nasopharyngeal swabs, sputum), urine (catheterized and midstream), and wound swabs (surface and deep tissue samples).
• Geographic Coverage: The report analyzes trends across the Americas (including North America and Latin America), Europe, Middle East & Africa, and Asia-Pacific countries, with granular coverage of major economies and health markets.
• Key Companies: Roche Diagnostics International AG, Abbott Laboratories, Danaher Corporation, Thermo Fisher Scientific Inc., Siemens Healthineers AG, Becton, Dickinson and Company, bioMérieux SA, QIAGEN N.V., Bio-Rad Laboratories, Inc., and DiaSorin S.p.A.

Key Takeaways for Senior Decision-Makers

• Trends reveal a shift from traditional testing to molecular and immunoassay methods, enhancing diagnostic speed and specificity.
• Point-of-care devices and digital integration are increasingly supporting decentralized testing and real-time clinical decisions in diverse care settings.
• Expanded test panels and automation help laboratories address rising infection complexity while optimizing operational workflows.
• Strategic collaborations among manufacturers, CROs, and healthcare institutions drive validation of novel platforms and real-world data collection.
• Comprehensive data integration with electronic medical records strengthens infection control and surveillance initiatives.
• Regional disparities in regulatory and reimbursement landscapes require localized strategies for successful market entry and expansion.

Tariff Impact on Diagnostic Supply Chains and Market Dynamics

Revised United States tariffs in 2025 have created cost pressures for manufacturers dependent on imported diagnostic reagents and instruments. This development has led companies to diversify supply chains, pursue dual-sourcing, and enhance regional distribution to manage procurement risks. Tariff-induced challenges further incentivize laboratories to conserve reagents and adopt multiplex assays, maximizing data yield from each test run. Ongoing industry-government dialogues are shaping strategies for critical material availability and cost stabilization, as laboratories and vendors adjust budgets and longer-term contracts accordingly.

Methodology & Data Sources

This report draws on primary interviews with clinical microbiologists, laboratory managers, regulatory professionals, and procurement experts, complemented by secondary research from peer-reviewed journals, regulatory filings, and industry white papers. Data triangulation and input from an expert advisory panel ensured findings are both evidence-based and relevant to current market needs.

Why This Report Matters

• Delivers actionable intelligence for executives managing product strategy, supply chain risk, or new market entry in the healthcare-associated infectious disease diagnostics space.
• Equips leaders with a reliable framework to align investments, partnerships, and operational initiatives with emerging clinical priorities and regulatory requirements.

Conclusion

The healthcare-associated infectious disease diagnostics market continues to adapt to technological innovations, regulatory changes, and evolving end-user demands. Informed planning and investment based on these findings can position organizations for lasting growth and resilience within this essential healthcare segment.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.